Human 90 kDa heat shock protein Hsp90 as a target for cancer therapeutics

Current Chemical Biology

Volumn 3, Issue 1, 2009, Pages 10-21

  Gava, Lisandra M ^a   Ramos, Carlos H I ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Antitumor drugs; Cancer therapeutics; Geldanamycin; Hsp90 inhibitors; Medicinal chemistry; Molecular chaperone

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHAPERONE; CISPLATIN; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IMATINIB; KF 58333; MACBECIN; NOVOBIOCIN; PACLITAXEL; PU 3; RADICICOL; SNX 2112; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CLINICAL TRIAL; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LIVER TOXICITY; MELANOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; STRUCTURE ANALYSIS;

EID: 65549114190     PISSN: 18723136     EISSN: None     Source Type: Journal    
DOI: 10.2174/2212796810903010010     Document Type: Review

References (130)

1. Ramos CHI, Ferreira ST. Protein folding, misfolding and aggregation: evolving concepts and conformational diseases. Protein Pept Lett 2005; 12: 213-22.
2. Dyson HJ, Wright PE. Intrinsically unstructured proteins and their functions. Nat Rev Mol Cell Biol 2005; 6:197-208.
3. Fandrich M, Fletcher MA, Dobson CM. Amyloid fibrils from muscle myoglobin. Nature 2001; 410: 165-66.
4. Fandrich M, Dobson CM. The behaviour of polyamino acids reveals an inverse side chain effect in amyloid structure formation. EMBO J 2002; 21: 5682-90.
5. Dobson CM. Experimental investigation of protein folding and misfolding. Methods 2004; 34: 4-14.
6. Minton AP. Implications of macromolecular crowding for protein assembly. Curr Op Struct Biol 2000; 10:34-9.
7. Prusiner SB. Shattuck lecture - neurodegenerative diseases and prions. N Engl J Med 2001; 344:1516-26.
8. Beissinger M, Buchner J. How chaperones fold proteins. Biol Chem 1998; 379: 245-59.
9. Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol, from nascent chain to folded protein. Science 2002; 295: 1852-8.
10. Borges JC, Ramos CHI. Protein folding assisted by chaperones. Protein Pept Lett 2008; 12: 256-61.
11. Borges JC, Peroto MC, Ramos CHI. Molecular Chaperone Genes in the SugarCane Expressed Sequence Database (SUCEST). Gen Mol Biol 2001; 24: 85-92.
12. Borges JC, Cagliari TC, Ramos CHI. Expression and variability of molecular chaperones in the sugarcane expressome. J Plant Physiol 2007; 164: 505-513.
13. Cagliari TC, Tiroli AO, Borges JC, Ramos CHI. Identification and in silico expression analysis of eucalyptus expressed sequencing tags (ESTs) encoding molecular chaperones. Gen Mol Biol 2005; 28: 520-8.
14. Csermely P. Chaperone overload is a possible contributor to 'civilization diseases'. Trends Genet 2001; 17: 701-4.
15. Chaduri TK, Paul S. Protein-misfolding diseases and chaperone-base therapeutic approaches. FEBS J 2006; 273: 1331-49.
16. Sõti C, Nagy E, Giricz Z, Vígh L, Csermely P, Ferdinandy P. Heat shock proteins as emerging therapeutic targets. Br J Pharmacol 2005; 146: 769-80.
17. Macario AJL, de Macario EC. Chaperonophaties and chaperonotherapy. FEBS Lett 2007; 581: 3681-8.
18. Powers MV, Workman P. Inhibitors of the heat shock response: Biology and pharmacology. FEBS Lett 2007; 581: 3758-69.
19. Turbyville TJ, Wijeratne EM, Whitesell L, Gunatilaka AA. The anticancer activity of the fungal metabolite terrecyclic acid A is associated with modulation of multiple cellular stress response pathways. Mol Cancer Ther 2005; 4: 1569-76.
20. Westerheide SD, Bosman JD, Mbadugha BN, et al. Celastrols as inducers of the heat shock response and cytoprotection. J Biol Chem 2004; 279: 56053-60.
21. Nagai N, Nakai A, Nagata K. Quercetin suppresses heat shock response by down regulation of HSF1. Biochem Biophys Res Commun 1995; 208: 1099-1105.
22. Dechsupa S, Kothan S, Vergote J, et al. Quercetin, Siamois 1 and Siamois 2 induce apoptosis in human breast cancer MDA-MB-435 cells xenograft in vivo. Cancer Biol Ther 2007; 6: 56-61.
23. Prodromou C, Pearl LH. Structure and functional relationships of Hsp90. Curr Cancer Drug Targets 2003; 3: 301-23.
24. Prodomou C, Roe SM, O'brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997; 90: 65-75.
25. Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997; 89: 239-50.
26. Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J Biol Chem 2000; 275: 37181-6.
27. Garnier C, Lafitte D, Tsvetkov PO, et al. Binding of ATP to heat shock protein 90: evidence for an ATP-binding site in the C-terminal domain. J Biol Chem 2002; 277: 12208-14.
28. Soti C, Racz A, Csermely P. A nucleotide-dependent molecular switch controls ATP binding at the C-terminal domain of Hsp90. N-terminal nucleotide binding unmasks a C-terminal binding pocket. J Biol Chem 2002; 277: 7066-75.
29. Obermann WM, Sondermann H, Russo AA, Pavletich NP, Hartl FU. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis. J Cell Biol 1998; 143: 901-10.
30. Jez JM, Chen JC, Rastelli G, Stroud RM, Santi DV. Crystal Structure and Molecular Modeling of 17-DMAG in Complex with Human Hsp90. Chem Biol 2003; 10: 361-8.
31. Boston RS, Viitanen PV, Vierling E. Molecular chaperones and protein folding in plants. Plant Mol Biol 1996; 32: 191-222.
32. Sreedhar AS, Kalmár E, Csermely P, Shen YF. Hsp90 isoforms: functions, expression and clinical importance. FEBS Lett 2004; 562: 11-5.
33. Eustace BK, Sakurai T, Stewart JK, et al. Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness. Nat Cell Biol 2004; 6: 507-14.
34. Wegele H, Müller L, Buchner J. Hsp70 and Hsp90 - a relay team for protein folding. Rev Physiol Biochem Pharmacol 2004; 151: 1-44.
35. Wandinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008; 283: 18473-7.
36. Chiosis G, Vilenchik M, Kim J, Solit D. Hsp90: the vulnerable chaperone. Drug Discov Today 2004; 9: 881-8.
37. Russell LC, Whitt SR, Chen MS, Chinkers M. Identification of conserved residues required for the binding of a tetratricopeptide repeat domain to heat shock protein 90. J Biol Chem 1999; 274: 20060-3.
38. Panaretou B, Siligardi G, Meyer P, et al. Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol Cell 2002; 10:1307-18.
39. Kamal A, Thao L, Sensintaffar J, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003; 425: 407-10.
40. Zhao R, Davey M, Hsu YC, et al. Navigating the chaperone network: an integrative map of physical and genetic interactions mediated by the hsp90 chaperone. Cell 2005; 120: 715-27.
41. Whitesell L, Lindquist SL. HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761-72.
42. Pratt WB. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc Soc Exp Biol Med 1998; 217: 420-34.
43. Nardai G, Végh EM, Prohászka Z, Csermely P. Chaperone-related immune dysfunction: an emergent property of distorted chaperone networks.Trends Immunol 2006; 27: 74-9.
44. Citri A, Harari D, Shohat G, et al. Hsp90 recognizes a common surface on client kinases. J Biol Chem 2006; 281: 14361-9.
45. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008; 410: 439-53.
46. Csermely P, Schnaider T, Soti C, Prohaszka Z, Nardai G. The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review. Pharmacol Ther 1998; 79: 129-68.
47. Buchner J. Hsp90 & Co. a holding for folding. Trends Biochem Sci 1999; 24: 136-41.
48. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
49. Workman P. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 2004; 206: 149-57.
50. Sharp S, Workman P. Inhibitors of the HSP90 molecular chaperone: current status. Adv Cancer Res 2006; 95: 323-48.
51. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007; 32: 517-30.
52. Fortugno P, Beltrami E, Plescia J, et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci 2003; 100: 13791-6.
53. Becker B, Multhoff G, Farkas B, et al. Induction of Hsp90 protein expression in malignant melanomas and melanoma metastases. Exp Dermatol 2004; 13: 27-32.
54. Eustace BK, Jay DG. Extracellular roles for the molecular chaperone, hsp90. Cell Cycle 2004; 3: 1098-100.
55. Sreedhar AS, Csermely P. Heat shock proteins in the regulation of apoptosis: new strategies in tumor therapy: a comprehensive review. Pharmacol Ther 2004; 101: 227-57.
56. Munster PN, Basso A, Solit D, Norton L, Rosen N. Modulation of Hsp90 function by ansamycins sensitizes breast cancer cells to chemotherapy-induced apoptosis in an RB- and schedule-dependent manner. Clin Cancer Res 2001; 7: 2228-36.
57. Munster PN, Marchion DC, Basso AD, Rosen N. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res 2002; 62: 3132-7.
58. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, Rosen N. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 2002; 277: 39858-66.
59. Sreedhar AS, Mihaly K, Pato B, et al. Hsp90 inhibition accelerates cell lysis. Anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide- and Hsp90-dependent events. J Biol Chem 2003; 278: 35231-40.
60. Sreedhar AS, Nardai G, Csermely P. Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors. Immunol Lett 2004; 92: 157-61.
61. Csermely P, Agoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005; 26: 178-82.
62. Neckers L, Neckers K. Heat-shock protein 90 inhibitors as novel cancer chemotherapeutics - an update. Expert Opin Emerg Drugs 2005; 10: 137-49.
63. Janin YL. Heat shock protein 90 inhibitors. A text book example of medicinal chemistry? J Med Chem 2005; 48: 7503-12.
64. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008; 13: 38-43.
65. Wehrli W. Ansamycins. Chemistry, biosynthesis and biological activity.Top Curr Chem 1977; 72: 21-49.
66. Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH. Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. Cell 1997; 90: 65-75.
67. Sasaki K, Yasuda H, Onodera K. Growth inhibition of virus transformed cells in vitro and antitumor activity in vivo of geldanamycin and its derivatives. J Antibiot 1979; 32: 849-51.
68. Whitesell L, Mimnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. Proc Natl Acad Sci 1994; 91: 8324-8.
69. Bagatell R, Paine-Murrieta GD, Taylor CW, et al. Induction of a heat shock factor 1-dependent stress response alters the cytotoxic activity of hsp90-binding agents. Clin Cancer Res 2000; 6: 3312-8.
70. Sittler A, Lurz R, Lueder G, et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. Hum Mol Genet 2001; 10: 1307-15.
71. Neckers L, Ivy SP. Heat shock protein 90. Curr Opin Oncol 2003; 15: 419-24.
72. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995; 36: 305-15.
73. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM, Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol 2001; 47: 291-302.
74. Patel K, Piagentini M, Rascher A, et al. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition. Chem Biol 2004; 11: 1625-33.
75. Xie Q, Gao CF, Shinomiya N, et al. Geldanamycins exquisitely inhibit HGF/SF-mediated tumor cell invasion. Oncogene 2005; 24: 3697-707.
76. Schulte TW, Neckers LM. The benzoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin. Cancer Chemother Pharmacol 1998; 42: 273-279.
77. Chiosis G, Huezo H, Rosen N, Mimnaugh E, Whitesell L, Neckers L. 17AAG: low target binding affinity and potent cell activity - finding an explanation. Mol Cancer Ther 2003; 2: 123-9.
78. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2003; 2: 131-8.
79. Banerji U, O'donnell A, Scurr M, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23: 4152-61.
80. Sausville EA, Tomaszewski JE, Ivy P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 2003; 3: 377-83.
81. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25: 5410-7.
82. Powers MV, Workman P. Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 2007; 581: 3758-69.
83. Banerji U, Affolter A, Judson I, Marais R, Workman P. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors. Mol Cancer Ther 2008; 7: 737-9.
84. De Candia P, Solit DB, Giri D, et al. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors. Proc Natl Acad Sci 2003; 100: 12337-42.
85. Bisht KS, Bradbury CM, Mattson D. Geldanamycin and 17- allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signalling and cytotoxicity. Cancer Res 2003; 63: 8984-95.
86. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM. Comparison of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005; 56(2): 126-37.
87. Egorin MJ, Lagattuta TF, Hamburger DR, et al. Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino) -17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats. Cancer Chemother Pharmacol 2002; 49(1): 7-19.
88. Phillips JJ, Yao ZP, Zhang W, et al. Conformational dynamics of the molecular chaperone Hsp90 in complexes with a co-chaperone and anticancer drugs. J Mol Biol 2007; 372(5): 1189-203.
89. Delmotte P, Delmotte-Plaque J. A new antifungal substance of fungal origin. Nature 1953; 171: 344.
90. Kwon HJ, Yoshida M, Abe K, Horinouchi S, Beppu T. Radicicol, an agent inducing the reversal of transformed phenotypes of src-transformed fibroblasts. Biosci Biotechnol Biochem 1992; 56(3): 538-9.
91. Soga S, Neckers LM, Schulte TW, et al. KF25706, a novel oxime derivative of radicicol, exhibits in vivo antitumor activity via selective depletion of Hsp90 binding signaling molecules. Cancer Res 1999; 59(12): 2931-8.
92. Agatsuma T, Ogawa H, Akasaka K, et al. Halohydrin and oxime derivatives of radicicol: synthesis and antitumor activities. Bioorg Med Chem 2002; 10(11): 3445-54.
93. Soga S, Shiotsu Y, Akinaga S, Sharma SV. Development of radicicol analogues. Curr Cancer Drug Targets 2003; 3(5): 359-69.
94. Marcu MG, Schulte TW, Neckers L. Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. J Natl Cancer Inst 2000; 92(3): 242-8.
95. Yu XM, Shen G, Neckers L, et al. Hsp90 inhibitors identified from a library of novobiocin analogues. J Am Chem Soc 2005; 127(37): 12778-9.
96. Llauger L, He H, Kim J, et al. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J Med Chem 2005; 48(8): 2892-905.
97. He H, Zatorska D, Kim J, et al. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J Med Chem. 2006; 49(1): 381-90.
98. Sharp SY, Prodromou C, Boxall K, et al. Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. Mol Cancer Ther 2007; 6(4): 1198-211.
99. Eccles SA, Massey A, Raynaud FI, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68(8): 2850-60.
100. Martin CJ, Gaisser S, Challis IR, et al. Molecular characterization of macbecin as an hsp90 inhibitor. J Med Chem 2008; 51(9): 2853-7.
101. Modi S, Stopeck AT, Gordon MS, et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 2007; 25(34): 5410-7.
102. Sydor JR, Normant E, Pien CS, et al. Development of 17- allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90. Proc Natl Acad Sci 2006; 103(46):17408-13.
103. Onodera H, Kaneko M, Takahashi Y, et al. Conformational significance of EH21A1-A4, phenolic derivatives of geldanamycin, for Hsp90 inhibitory activity. Bioorg Med Chem Lett 2008; 18(5): 1577-80.
104. Banerji U, Sain N, Sharp SY, et al. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino- 17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer Chemother Pharmacol 2008; 62(5): 769-78.
105. Chandarlapaty S, Sawai A, Ye Q, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res 2008; 14(1): 240-48.
106. Yu X, Guo ZS, Marcu MG, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002; 94(7): 504-13.
107. Aoyagi S, Trevor K. Archer Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends in Cell Biology 2005; 15(11): 565-7.
108. Martínez-Ruiz A, Villanueva L, González de Orduña C, et al. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities. Proc Natl Acad Sci 2005; 102(24):8525-30.
109. Legagneux V, Morange M, Bensaude O.Heat shock increases turnover of 90 kDa heat shock protein phosphate groups in HeLa cells. FEBS Lett 1991; 291(2): 359-62.
110. Zhao YG, Gilmore R, Leone G, Coffey MC, Weber B, Lee PW. Hsp90 phosphorylation is linked to its chaperoning function. Assembly of the reovirus cell attachment protein. J Biol Chem 2001; 276(35): 32822-7.
111. Kurokawa M, Zhao C, Reya T, Kornbluth S. Inhibition of apoptosome formation by suppression of Hsp90beta phosphorylation in tyrosine kinase-induced leukemias. Mol Cell Biol 2008; 28(17): 5494-506.
112. Beere H. Death versus survival: functional interaction between the apoptotic and stress-inducible heat shock protein pathways. J Clin Invest 2005; 115: 2633-9.
113. Gorre ME, Ellwood-Yen K, Chiosis G, Rosen N, Sawyers CL. BCRABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90. Blood 2002; 100: 3041-4.
114. Srivastava PK, Maki RG. Stress-induced proteins in immune response to cancer.Curr Top Microbiol Immunol 1991; 167: 109-23.
115. Ishii T, Udono H, Yamano T, et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins hsp70, hsp90, and gp96. J Immunol 1999; 162(3):1303-9.
116. Callahan MK, Garg M, Srivastava PK. Heat-shock protein 90 associates with N-terminal extended peptides and is required for direct and indirect antigen presentation.Proc Natl Acad Sci 2008; 105(5):1662-7.
117. Brodsky JL, Chiosis G. Hsp70 molecular chaperones: emerging roles in human disease and identification of small molecule modulators. Curr Top Med Chem 2006; 6: 1215-25.
118. Johnson JL, Beito TG, Krco CJ, Toft DO. Characterization of a novel 23-kilodalton protein of unactive progesterone receptor complexes. Mol Cell Biol 1994; 14: 1956-63.
119. Kimura Y, Rutherford SL, Miyata Y. Cdc37 is a molecular chaperone with specific functions in signal transduction. Genes Dev 1997; 14: 1775-85.
120. Mayer MP, Nikolay R, Bukau B. Aha, another regulator for hsp90 chaperones. Mol Cell 2002; 6: 1255-6.
121. Perdew GH, Whitelaw ML. Evidence that the 90-kDa heat shock protein (HSP90) exists in cytosol in heteromeric complexes containing HSP70 and three other proteins with Mr of 63,000,56,000, and 50,000. J Biol Chem 1991; 266: 6708-13.
122. Johnson BD, Schumacher RJ, Ross ED, Toft DO. Hop modulates Hsp70/Hsp90 interactions in protein folding. J Biol Chem 1998; 6: 3679-86.
123. Young JC, Hoogenraad NJ, Hartl FU. Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. Cell 2003; 1: 41-50.
124. Catlett MG, Kaplan KB. Sgt1p is a unique co-chaperone that acts as a client adaptor to link Hsp90 to Skp1p. J Biol Chem 2006; 44: 33739-48.
125. Liu L, Srikakulam R, Winkelmann DA. Unc45 activates Hsp90-dependent folding of the myosin motor domain. J Biol Chemjavascript:AL_get(this, 'jour', 'J Biol Chem.'); 2008; 19: 13185-93.
126. Pirkl F, Buchner J. Functional analysis of the Hsp90-associated human peptidyl prolyl cis/trans isomerases FKBP51, FKBP52 and Cyp40. J Mol Biol 2001; 4: 795-806.
127. Warth R, Briand PA, Picard D. Functional analysis of the yeast 40 kDa cyclophilin Cyp40 and its role for viability and steroid receptor regulation. Biol Chem 1997; 5: 381-91.
128. Silverstein AM, Galigniana MD, Chen MS, Owens-Grillo JK, Chinkers M, Pratt WB. Protein phosphatase 5 is a major component of glucocorticoid receptor.hsp90 complexes with properties of an FK506-binding immunophilin. J Biol Chem 1997; 26: 16224-30.
129. Connell P, Ballinger CA, Jiang J, et al. The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins. Nat Cell Biol 2001; 3: 93-6.
130. Rosser MF, Washburn E, Muchowski PJ, Patterson C, Cyr DM. Chaperone functions of the E3 ubiquitin ligase CHIP. J Biol Chem 2007; 31: 22267-77.